Julie N Graff

7PUBLICATIONS
102CO-AUTHORS
Molecular targetsPredictive and prognostic markersRadiation therapyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 05, 2026
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types.

Ya-Mei Hu, Faming Zhao, Julie N Graff

|Nov 26, 2025
Elevated tumor-associated androgen receptor activity correlates with poor immune infiltration and immunotherapy response across cancer types.

Ya-Mei Hu, Faming Zhao, Julie N Graff

|Oct 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching

|Oct 07, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Gerhardt Attard, Neeraj Agarwal, Julie N Graff

|Feb 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.

Matthew D Galsky, Karen A Autio, Christopher R Cabanski

|Dec 09, 2024
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.

Lisa N Chesner, Fanny Polesso, Julie N Graff

Pageof 2

Frequent Collaborators

3 joint publications

Amy E Moran

3 joint publications

Zheng Xia

3 joint publications

Faming Zhao

3 joint publications

Ya-Mei Hu